OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com
Clinical Trials
Related News

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

First Posted Date
2014-08-08
Last Posted Date
2016-07-07
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT02212613
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

First Posted Date
2014-07-22
Last Posted Date
2018-08-21
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
837
Registration Number
NCT02196506

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

Phase 3
Completed
Conditions
Schizophrenia With Impulsivity
Interventions
Drug: Brexpiprazole
First Posted Date
2014-07-21
Last Posted Date
2018-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
38
Registration Number
NCT02194933
Locations
🇺🇸

University of California at Irvine Medical Center, Orange, California, United States

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

First Posted Date
2014-07-17
Last Posted Date
2018-04-30
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
450
Registration Number
NCT02192554

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

First Posted Date
2014-06-26
Last Posted Date
2022-02-18
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
56
Registration Number
NCT02174822
Locations
🇦🇺

Nucleus Network, Melbourne, Victoria, Australia

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

First Posted Date
2014-06-10
Last Posted Date
2018-08-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
1370
Registration Number
NCT02160145

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

First Posted Date
2014-03-19
Last Posted Date
2021-10-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
30
Registration Number
NCT02091882

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Vehicle ointment
Drug: OPA-15406
First Posted Date
2014-02-21
Last Posted Date
2021-11-23
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
121
Registration Number
NCT02068352

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
Drug: Brexpiprazole
First Posted Date
2014-02-04
Last Posted Date
2015-12-30
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
97
Registration Number
NCT02054702

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

First Posted Date
2014-01-31
Last Posted Date
2014-01-31
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
47
Registration Number
NCT02050854
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy